Belgian atopic dermatitis guidelines

被引：2

作者：

Lapeere, Hilde ^{[1
]}

Speeckaert, Reinhart ^{[1
]}

Baeck, Marie ^{[2
]}

Dezfoulian, Bita ^{[3
]}

Lambert, Julien ^{[4
]}

Roquet-Gravy, Pierre-Paul ^{[5
]}

Stockman, Annelies ^{[6
]}

White, Jonathan ^{[7
]}

Castelijns, Francisca ^{[8
]}

Gutermuth, Jan ^{[9
]}

机构：

[1] Ghent Univ Hosp, Dept Dermatol, Ghent, Belgium

[2] Catholic Univ Louvain, Clin Univ St Luc, Dept Dermatol, Brussels, Belgium

[3] Liege Univ Hosp, Dept Dermatol, Liege, Belgium

[4] Univ Hosp Antwerp UZA, Dept Dermatol, Edegem, Belgium

[5] Grand Hop Charleroi, Dept Dermatol, Charleroi, Belgium

[6] AZ Delta, Dept Dermatol, Campus Rembert Torhout, Torhout, Belgium

[7] Univ Libre Bruxelles, Hop Erasme, Dept Dermatol, Brussels, Belgium

[8] Univ Hosp Leuven, Dept Dermatol, Leuven, Belgium

[9] Vrije Univ Brussel VUB, Universitair Ziekenhuis Brussel, Dept Dermatol, Brussels, Belgium

来源：

ACTA CLINICA BELGICA | 2024年 / 79卷 / 01期

关键词：

Atopic dermatitis; diagnosis; therapy; guideline; eczema; REDUCE STAPHYLOCOCCUS-AUREUS; TASK-FORCE; POSITION PAPER; DOUBLE-BLIND; FLUTICASONE PROPIONATE; MAINTENANCE TREATMENT; EUROPEAN GUIDELINES; INDUCED ERYTHEMA; FOOD ALLERGY; ECZEMA;

D O I：

10.1080/17843286.2023.2285576

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Atopic dermatitis (AD) is one of the most common, bothersome and difficult to treat skin disorders. Recent introduction of new systemic treatments has revolutionized the management of AD. The goal of this guideline is to provide evidence-based recommendations for the management of patients suffering from atopic dermatitis that easily can be implemented in clinical practice. These recommendations were developed by 11 Belgian AD experts. Comments of all experts on the proposed statements were gathered, followed by an online voting session. The most relevant strategies for the management and treatment of AD in the context of the Belgian health care landscape are discussed. General measures, patient education and adequate topical treatment remain the cornerstones of AD management. For moderate to severe AD, the introduction of biologics and JAK inhibitors show unprecedented efficacy, although currently access is limited to a subgroup of patients meeting the reimbursement criteria.

引用

页码：62 / 74

页数：13

共 75 条

[1] Topical corticosteroid phobia in atopic dermatitis: a study of its nature, origins and frequency [J].